These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39358778)

  • 1. In vitro drug testing using patient-derived ovarian cancer organoids.
    Chen LY; Chou YT; Liew PL; Chu LH; Wen KC; Lin SF; Weng YC; Wang HC; Su PH; Lai HC
    J Ovarian Res; 2024 Oct; 17(1):194. PubMed ID: 39358778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
    Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
    J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.
    Chang YH; Wu KC; Wang KH; Ding DC
    Cell Transplant; 2024; 33():9636897241281869. PubMed ID: 39323050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
    de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
    Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
    Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
    Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
    Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
    Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
    J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development.
    Xiang D; He A; Zhou R; Wang Y; Xiao X; Gong T; Kang W; Lin X; Wang X; ; Liu L; Chen YG; Gao S; Liu Y
    Theranostics; 2024; 14(8):3300-3316. PubMed ID: 38855182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.
    Zhao Y; Li S; Zhu L; Huang M; Xie Y; Song X; Chen Z; Lau HC; Sung JJ; Xu L; Yu J; Li X
    Cell Rep Med; 2024 Jul; 5(7):101627. PubMed ID: 38964315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    Tao M; Wu X
    J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Maru Y; Tanaka N; Itami M; Hippo Y
    Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
    Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
    Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
    Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N
    Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
    Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
    Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
    Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
    Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.